Use of an interferon-gamma based assay to assess bladder cancer patients treated with intravesical BCG and exposed to tuberculosis Journal Articles uri icon

  • Overview
  • Research
  • Identity
  • Additional Document Info
  • View All


  • OBJECTIVE: Compare the QuantiFERON-TB Gold In-Tube (QFT) assay and the tuberculin skin test (TST) in bladder cancer patients receiving high dose BCG therapy (BCG patients). DESIGN AND METHODS: BCG patients and healthy visitors, both exposed to tuberculosis, were screened with a TST and QFT. RESULTS: QFT-TST correlation was excellent in visitors, but poor in BCG patients. BCG therapy predicted a positive TST (p<0.001) but not a positive QFT (p=0.35). DISCUSSION: The management of BCG patients was impacted, by measuring the QFT.


  • Silverman, MS
  • Reynolds, D
  • Kavsak, Peter
  • Garay, J
  • Daly, A
  • Davis, I

publication date

  • August 2007